METHODS: In this retrospective study, patients treated with camrelizumab plus antiangiogenic therapy (bevacizumab, anlotinib, or recombinant human endostatin) were included. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), quality of life (QOL) assessed by ECOG PS, and safety were analyzed.
RESULTS: Between January 10, 2019, and February 28, 2024, a total of 59 patients were included. The ORR was 35.6% (21/59) and the DCR was 86.4%. With a median follow-up of 10.5 months (range: 0.7-23.7), the median PFS was 5.5 months (95% confidence interval [CI]: 3.8-7.3) and the median OS was 10.5 months (95% CI: 11.2-13.6). QOL was improved (≥1 reduction in ECOG PS) in 39 patients (66.1%). The most common Grade 3-4 treatment-related adverse events were hepatic dysfunction (6 [10%]), hypertension (5 [8%]), and hypothyroidism (3 [5%]). There were no treatment-related deaths.
CONCLUSIONS: Third- or further-line immunotherapy combined with antiangiogenic therapy is well-tolerated and shows good antitumor activity in stage IV NSCLC patients with ECOG PS 2. Future large-scale prospective studies are required to confirm the clinical benefits of this combination therapy.
方法:在这项回顾性研究中,卡姆瑞珠单抗联合抗血管生成治疗的患者(贝伐单抗,安洛替尼,或重组人内皮抑素)包括在内。客观反应率(ORR),疾病控制率(DCR),无进展生存期(PFS),总生存期(OS),通过ECOGPS评估生活质量(QOL),并对安全性进行了分析。
结果:在2019年1月10日至2024年2月28日之间,共包括59例患者。ORR为35.6%(21/59),DCR为86.4%。中位随访时间为10.5个月(范围:0.7-23.7),中位PFS为5.5个月(95%置信区间[CI]:3.8~7.3),中位OS为10.5个月(95%CI:11.2~13.6).39例(66.1%)患者的生活质量得到改善(ECOGPS降低≥1)。最常见的3-4级治疗相关不良事件是肝功能障碍(6[10%]),高血压(5[8%]),和甲状腺功能减退(3[5%])。没有治疗相关的死亡。
结论:三线或进一步的免疫治疗联合抗血管生成治疗在患有ECOGPS2的IV期NSCLC患者中具有良好的耐受性和良好的抗肿瘤活性。未来需要大规模的前瞻性研究来证实这种联合治疗的临床益处。